^
Association details:
| Biomarker: | CD20 positive |
|---|---|
| Cancer: | Non-Hodgkin’s Lymphoma |
| Drug: | Rituxan (rituximab) (CD20 inhibitor) + anzurstobart (BMS-986351) (SIRPA antagonist) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
FIRST CLINICAL STUDY OF THE ANTI-SIGNAL REGULATORY PROTEIN-ALPHA (SIRPΑ) ANTIBODY CC-95251 COMBINED WITH RITUXIMAB IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) NON-HODGKIN LYMPHOMA (NHL)
Published date:
05/12/2022
Excerpt:
CC-95251 + ritux demonstrated a manageable safety profile and promising efficacy in pts with heavily pretreated CD20+ R/R NHL.
Trial ID:
